Pharmaceutical Composition for Neurological Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The compound (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol exhibits low solubility in aqueous media and undergoes significant oxidation, leading to poor oral absorption and systemic exposure due to first-pass metabolism, which limits its effectiveness in treating neurological disorders.
Innovation Solution
Development of pharmaceutical compositions comprising (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol and its pharmaceutically acceptable salts, optimized with specific excipients to enhance solubility and bioavailability, including formulations for controlled release and administration routes like subcutaneous, intranasal, and intravenous to improve brain penetration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol is administered orally, then it can be delivered to the patient, but low solubility and first-pass metabolism result in poor systemic exposure and brain penetration
Solution Approach 1:
The patent employs salt formation to change the chemical form of the compound, transforming it from a free base with poor solubility to a salt form with improved dissolution properties. This parameter change in molecular form directly addresses the solubility issue while maintaining the ability to cross the blood-brain barrier
Solution Approach 2:
The patent uses solubility enhancers and formulation excipients as intermediary substances that facilitate the dissolution and absorption of the active compound without being consumed. These intermediaries bridge the gap between the poorly soluble API and the aqueous gastrointestinal environment, enabling sufficient systemic exposure
2Quantity of substance
If the compound is formulated to improve solubility, then aqueous solubility increases, but oxidation and decomposition in liquid solutions occur
Solution Approach 1:
The patent incorporates antioxidants and stabilizers into the formulation before administration, performing protective action in advance. These preliminary protective measures prevent oxidation and decomposition that would otherwise occur when the compound is in contact with aqueous media in the gastrointestinal tract
Solution Approach 2:
The formulation creates a protective chemical environment using antioxidants that scavenge oxygen and free radicals, effectively establishing an inert-like atmosphere around the active compound. This protective environment prevents oxidative degradation while the compound dissolves and is absorbed
3Object-affected harmful factors
If Cmax is reduced to improve safety, then toxicity decreases, but brain penetration via passive diffusion is compromised
Solution Approach 1:
The patent employs controlled-release formulation technology that dynamically adjusts the release rate of the active compound over time. This creates a sustained, lower Cmax profile that maintains adequate brain concentrations through prolonged exposure rather than peak concentration, balancing safety and efficacy
Data Source
AI summary
The present invention relates to pharmaceutical compositions for administration to mammals that include (6aS)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol or a pharmaceutically acceptable salt thereof and at least one pharmaceutically acceptable excipient that provides pharmacokinetic profiles useful for the treatment of neurodegenerative diseases.